References
1. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors. Washington, DC: The National Academies Press; 2011. 290 p.
2. Campsall P, Colizza K, Straus S, Stelfox HT. Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study. PLoS Med. 2016;13(5):e1002029.
3. Cosgrove L, Bursztajn HJ, Erlich DR, Wheeler EE, Shaughnessy AF. Conflicts of interest and the quality of recommendations in clinical guidelines. J Eval Clin Pract. 2013;19(4):674-81.
4. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. J Med Ethics. 2009;35(5):283-8.
5. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356(4):331-3.
6. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel Review Working G. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ. 2013;347:f5535.
7. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med. 2015;163(7):548-53.
8. Traversy G, Barnieh L, Akl EA, Allan GM, Brouwers M, Ganache I, et al. Managing conflicts of interest in the development of health guidelines. CMAJ. 2021;193(2):E49-E54.
9. Shigeta H, Murayama A, Kamamoto S, Saito H, Ozaki A. Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021. Cureus. 2023;15(3):e36567.
10. Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken). 2023;75(6):1278-86.
11. Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol. 2022;17(6):819-26.
12. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg. 2022;166(5):869-76.
13. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases. 2016;75(1):3.
14. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases — past, present and future. Nature Reviews Rheumatology. 2017;13(7):443-8.
15. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021. J Rheumatol. 2023;50(4):575-7.
16. Murayama A, Mamada H, Shigeta H, Yoshinaga T, Saito H, Yamashita E, et al. Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol. 2023;29(3):118-25.
17. Putman MS, Goldsher JE, Crowson CS, Duarte-Garcia A. Industry Payments to Practicing US Rheumatologists, 2014-2019. Arthritis Rheumatol. 2021;73(11):2138-44.
18. Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS One. 2020;15(10):e0239610.
19. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract. 2023;29(6):883-6.
20. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open. 2023;13(4):e068237.
21. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep. 2023;13(1):7425.
22. Medical Governance Research Institute. Yen For Docs [Online database]. Medical Governance Research Institute; 2023 [updated September 11, 2023. Available from:https://yenfordocs.jp/.
23. Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565-73.
24. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect. 2022;28(3):460-2.
25. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J. 2021;32(2):443-51.
26. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy. 2021;125(3):320-6.
27. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int. 2021;41(3):464-9.
28. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T, Akihiko O. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus. 2022;35(10).
29. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Letter to the editor: Are clinical practice guidelines for hepatitis C by the American Association for the Study of Liver Diseases and Infectious Diseases Society of America evidence based? Financial conflicts of interest and assessment of quality of evidence and strength of recommendations. Hepatology. 2022;75(4):1052-4.
30. Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest policies among organizations producing clinical practice guidelines. PLOS ONE. 2021;16(4):e0249267.
Table 1. Demographic characteristics of clinical practice guideline authors for rheumatologic arthritis inJapan